Mapping convergent regulators of melanoma drug resistance by PerturbFate

Zihan Xu1,2, Ziyu Lu3,4, Aileen Ugurbil3,5

  • 1Laboratory of Single-Cell Genomics and Population Dynamics, Rockefeller University, New York, NY, USA. zxu@rockefeller.edu.

Nature
|April 15, 2026
PubMed

Insights

We developed PerturbFate, a new single-cell platform to study gene regulation. This tool helps understand how genetic changes lead to shared cell states, aiding disease research.

Area of Science:

  • Genomics
  • Cell Biology
  • Biotechnology

Background:

  • High-throughput genomic studies reveal gene-disease links.
  • Understanding how diverse genetic changes cause similar cell states is difficult.

Purpose of the Study:

  • Introduce PerturbFate, a cost-effective, high-throughput single-cell platform.
  • Systematically analyze CRISPR interference perturbations across gene regulation.
  • Characterize multimodal responses to gene perturbations in melanoma cells.

Main Methods:

  • Developed PerturbFate, a combinatorial-indexing single-cell platform.
  • Performed massively parallel CRISPR interference perturbations.
  • Profiled over 300,000 cultured melanoma cells and 140 vemurafenib resistance-associated genes.

Main Results:

  • Uncovered a shared dedifferentiated cell state driven by cooperative transcription factor activity.
  • Linked Mediator complex component perturbations to convergent transcriptional activations.
  • Identified common regulatory nodes influencing similar phenotypic outcomes across genetic perturbations.

Conclusions:

  • PerturbFate enables systematic interrogation of gene regulation and cell states.
  • The platform facilitates discovery of molecular regulators linking gene perturbations to phenotypes.
  • Provides insights into how functionally unrelated gene perturbations reshape cell states.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K